[1]
D. Govindapala, “Reactogenicity and persistence of IgG antibodies against SARS-CoV-2 among recipients of ChAdOx1 nCoV-19 vaccine: A single center experience from Sri Lanka”, IJHS, vol. 17, no. 1, pp. 36–43, Dec. 2022.